Wall Street analysts forecast that Juno Therapeutics, Inc. (NASDAQ:JUNO) will post earnings of ($1.15) per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have made estimates for Juno Therapeutics’ earnings. Juno Therapeutics reported earnings per share of ($0.65) during the same quarter last year, which would indicate a negative year-over-year growth rate of 76.9%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, March 7th.
On average, analysts expect that Juno Therapeutics will report full-year earnings of ($3.34) per share for the current financial year. For the next financial year, analysts expect that the firm will report earnings of ($4.26) per share, with EPS estimates ranging from ($4.35) to ($4.17). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that cover Juno Therapeutics.
Juno Therapeutics (NASDAQ:JUNO) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.80) by $0.07. The firm had revenue of $44.80 million for the quarter, compared to analyst estimates of $18.12 million. Juno Therapeutics had a negative return on equity of 32.54% and a negative net margin of 332.05%. The business’s revenue was up 115.4% on a year-over-year basis. During the same period in the previous year, the company posted ($0.57) earnings per share.
In related news, insider Sunil Agarwal sold 7,285 shares of Juno Therapeutics stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $44.76, for a total transaction of $326,076.60. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Robert Azelby sold 6,666 shares of Juno Therapeutics stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $54.95, for a total value of $366,296.70. Following the transaction, the executive vice president now owns 79,998 shares in the company, valued at approximately $4,395,890.10. The disclosure for this sale can be found here. Company insiders own 15.08% of the company’s stock.
Large investors have recently bought and sold shares of the business. Advisor Group Inc. raised its position in Juno Therapeutics by 141.1% in the third quarter. Advisor Group Inc. now owns 2,459 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 1,439 shares during the period. The Manufacturers Life Insurance Company raised its position in Juno Therapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 228 shares during the period. Pacad Investment Ltd. purchased a new stake in Juno Therapeutics in the second quarter valued at $105,000. Bronfman E.L. Rothschild L.P. raised its position in Juno Therapeutics by 27,376.9% in the third quarter. Bronfman E.L. Rothschild L.P. now owns 3,572 shares of the biopharmaceutical company’s stock valued at $160,000 after purchasing an additional 3,559 shares during the period. Finally, QS Investors LLC purchased a new stake in Juno Therapeutics in the second quarter valued at $135,000. Institutional investors own 70.37% of the company’s stock.
Shares of Juno Therapeutics (NASDAQ:JUNO) traded down $3.24 during trading hours on Friday, hitting $44.17. The stock had a trading volume of 4,361,000 shares, compared to its average volume of 2,092,505. The company has a current ratio of 4.77, a quick ratio of 4.77 and a debt-to-equity ratio of 0.01. Juno Therapeutics has a 12-month low of $17.52 and a 12-month high of $63.45.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.